In a nutshell This study evaluated the association between statin (cholesterol-lowering drugs) use and survival outcomes in men with advanced prostate cancer (PC) undergoing androgen deprivation therapy (ADT). The data showed that statin use improved the survival outcomes in these patients. Some background Metastatic prostate cancer (PC) is a form of...
Read More
In a nutshell This study evaluated the effectiveness and safety of panitumumab (Vectibix) rechallenge when added to maintenance therapy with FOLFIRI {fluorouracil (FU; Adrucil), folinic acid (FA; Leucovorin), irinotecan (Camptosar)} in patients with RAS wild-type metastatic colorectal cancer (mCRC). The data showed that maintenance therapy with...
Read More
In a nutshell This study evaluated the effectiveness of chemotherapy before surgery for the treatment of patients with resectable colorectal cancer liver metastasis (CRLM). The data showed that the addition of chemotherapy before surgery significantly improved disease-free survival (survival without any signs or symptoms of cancer) but not the...
Read More
In a nutshell This study evaluated the effectiveness and safety of olaparib (Lynparza) with or without cediranib (Recentin) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that cediranib combined with olaparib significantly improved survival without cancer worsening compared with olaparib alone in these patients....
Read More
In a nutshell This study evaluated the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple-negative breast cancer (TNBC). This study concluded that the combination of taxanes and chemotherapy is effective with manageable side effects in these patients. Some background TNBC is a subtype of BC that tests...
Read More
In a nutshell The study evaluated the effectiveness and safety of radium-223 dichloride (Xofigo) treatment in real-world patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that radium-223 dichloride treatment was well tolerated and reduced pain in real-world patients with mCRPC spread to the bone. Some...
Read More
In a nutshell The study evaluated the safety and effectiveness of relatlimab (Opdualag) and nivolumab (Opdivo) combination therapy before surgery in patients with stages III and IV resectable melanoma. The study concluded that the relatlimab and nivolumab combination was safe and effective in these patients. Some background...
Read More
In a nutshell This study evaluated which sequence of treatment should be given first – immunotherapy or targeted therapy – for the most clinical benefit in patients with BRAF-mutated metastatic melanoma. The data showed that immunotherapy followed by targeted therapy significantly improved survival outcomes in these patients. Some background...
Read More
In a nutshell This study evaluated the effectiveness of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) for the treatment of patients with colorectal cancer liver metastasis (CRLM) at high risk. The data showed that NAC improved the overall survival of these patients. Some background Colorectal cancer (CRC) is one of the most common...
Read More
In a nutshell This study evaluated the effectiveness and safety of rezvilutamide (Ariane) versus bicalutamide (Casodex) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that rezvilutamide in combination with ADT significantly improved the...
Read More
In a nutshell This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) either alone or in combination for the treatment of patients with advanced melanoma. The data showed that nivolumab (Opdivo) and ipilimumab (Yervoy) combination therapy was more effective than nivolumab or ipilimumab alone for the treatment of...
Read More
In a nutshell This study evaluated the effectiveness of abemaciclib (Verzenio) alone or in combination with tamoxifen (Nolvadex) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC) resistant to hormone therapy. The data showed that abemaciclib in combination with tamoxifen was more effective in improving...
Read More
